[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342665-105":59,"doc-detail-342665-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-analysis-and-validation-reveal-depdc1-as-a-potential-diagnostic-biomarker-associated-with-tumor-immunity-in-non-small-cell-lung-cancer-research-report","Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer - Research report","","Current evidence suggests DEP domain containing 1 (DEPDC1) is important in non-small-cell lung cancer (NSCLC), yet its diagnostic value and regulatory function remain unclear. This study integrates publicly available databases with in vitro experiments to assess DEPDC1 expression, clinical associations, diagnostic performance, and molecular mechanisms. DEPDC1 is upregulated in NSCLC tissues, shows strong diagnostic accuracy (AUC 0.96), and high expression is validated in NSCLC cells by qRT-PCR and western blotting. Functional assays indicate that DEPDC1 knockdown targeting the P53 signaling pathway reduces proliferation and increases apoptosis. Immune analyses link DEPDC1 to infiltrating immune cell levels and show different immune checkpoint inhibitor scores between expression groups, supported by GSEA and immune-related pathway enrichment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-analysis-and-validation-reveal-depdc1-as-a-potential-diagnostic-biomarker-associated-with-tumor-immunity-in-non-small-cell-lung-cancer-research-report/342665/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-analysis-and-validation-reveal-depdc1-as-a-potential-diagnostic-biomarker-associated-with-tumor-immunity-in-non-small-cell-lung-cancer-research-report/342665.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical and diagnostic value does DEPDC1 have in NSCLC?","Question",{"text":112,"@type":113},"DEPDC1 is markedly upregulated in NSCLC tissues compared with non-carcinoma tissues. Summary ROC analysis indicates high diagnostic performance with AUC=0.96 and strong sensitivity and specificity estimates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DEPDC1 expression validated experimentally?",{"text":117,"@type":113},"DEPDC1 expression was assessed using quantitative real-time PCR (qRT-PCR) and western blotting, showing high expression in NSCLC cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What effect does DEPDC1 downregulation have on NSCLC cells and signaling pathways?",{"text":121,"@type":113},"Downregulated DEPDC1 targeting the P53 signaling pathway inhibited NSCLC cell proliferation and promoted apoptosis, as supported by in vitro MTS and apoptotic assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342665,1790230686,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","PLOS ONE  \nOPEN ACCESS  \nCitation: Lv M, Li X, Yin Z, Yang H, Zhou B (2024) Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer. PLoS ONE 19(4): e0294227 . [https://](https://)[ ](https://)[doi.org/10.1371/journal.pone.0294227](doi.org/10.1371/journal.pone.0294227)  \n[Editor:](Editor: Jincheng Wang)[ Jincheng Wang](Editor: Jincheng Wang), Hokkaido University: Hokkaido Daigaku, JAPAN  \nReceived: January 12, 2023  \nAccepted: October 20, 2023  \nPublished: April 2, 2024  \nCopyright: © 2024 Lv et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the paper and its Supporting Information files.  \nFunding: This research is supported by grant no. 82273720 from the National Natural Science Foundation of China. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This article did not receive any third party support in conducting this research,  \nRESEARCH ARTICLE  \nComprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-smallcell lung cancer  \nMeiwen Lv1, Xuelian Li2, Zhihua Yin2, He Yang1, Baosen Zhou1 *  \n1 Department of Clinical Epidemiology, The First Hospital of China Medical University, Heping District, Shenyang, China, 2 Department of Epidemiology, School of Public Health of China Medical University, Shenyang, China  \n* [bszhou@cmu.edu.cn](bszhou@cmu.edu.cn)  \nAbstract  \nCurrent evidence suggests that DEP domain containing 1 (DEPDC1) has an important effect on non-small-cell lung cancer (NSCLC) . However, the diagnostic value and the regulatory function within NSCLC are largely unclear. This work utilized publicly available databases and in vitro experiments for exploring, DEPDC1 expression, clinical features, diagnostic significance and latent molecular mechanism within NSCLC. According to our results, DEPDC1 was remarkably upregulated in the tissues of NSCLC patients compared with non-carcinoma tissues, linked with gender, stage, T classification and N classification based on TCGA data and associated with smoking status and stage according to GEO datasets. Meanwhile, the summary receiver operating characteristic (sROC) curve analysis result showed that DEPDC1 had a high diagnostic value in NSCLC (AUC = 0.96, 95% CI:  \n0.94–0.98; diagnostic odds ratio = 99.08, 95%CI: 31.91–307.65; sensitivity = 0.89, 95%CI:  \n0.81–0.94; specificity = 0.92, 95%CI: 0.86–0.96; positive predictive value = 0.94, 95%CI:  \n0.89–0.98; negative predictive value = 0.78, 95%CI: 0.67–0.90; positive likelihood ratio = 11.77, 95%CI: 6.11–22.68; and negative likelihood ratio = 0. 12, 95%CI: 0.06–0.22) . Subsequently, quantitative real-time PCR (qRT-PCR) and western blotting indicated that DEPDC1 was high expressed in NSCLC cells. According to the in vitro MTS and apoptotic assays, downregulated DEPDC1 expression targeting P53 signaling pathway inhibited the proliferation of NSCLC cells while promoting apoptosis of NSCLC cells. Moreover, DEPDC1 was significantly correlated with immune cell infiltrating levels in NSCLC based on TCGA data, which were primarily associated with T cells CD4 memory activated, macrophages M1, B cells memory, mast cells resting, T cells regulatory, monocytes, and T cells CD4 memory resting. Compared with the group with high expression of DEPDC1, the group with low expression level had higher scores for immune checkpoint inhibitors (ICIs) treatment. GSEA confirmed that DEPDC1 was involved in gene expression and tumor-related signaling pathways. Finally, DEPDC1 and its associated immune-related","cbCaiqYUVRKcRMO2","https://ap.wps.com/l/cbCaiqYUVRKcRMO2","pdf",2979388,"English","# Abstract\n## Diagnostic analysis\n## Expression validation\n## Functional assays\n## Immune infiltration and treatment relevance\n## Pathway and enrichment results\n# Introduction","[{\"question\":\"What clinical and diagnostic value does DEPDC1 have in NSCLC?\",\"answer\":\"DEPDC1 is markedly upregulated in NSCLC tissues compared with non-carcinoma tissues. Summary ROC analysis indicates high diagnostic performance with AUC=0.96 and strong sensitivity and specificity estimates.\"},{\"question\":\"How was DEPDC1 expression validated experimentally?\",\"answer\":\"DEPDC1 expression was assessed using quantitative real-time PCR (qRT-PCR) and western blotting, showing high expression in NSCLC cells.\"},{\"question\":\"What effect does DEPDC1 downregulation have on NSCLC cells and signaling pathways?\",\"answer\":\"Downregulated DEPDC1 targeting the P53 signaling pathway inhibited NSCLC cell proliferation and promoted apoptosis, as supported by in vitro MTS and apoptotic assays.\"}]","Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer - Research report | PDF",1790047647,48]